JINYU(SH:600201) Zhi Tong Cai Jing·2025-12-10 10:14Core Viewpoint - Junshi Biosciences has submitted an application for listing on the Hong Kong Stock Exchange, aiming to advance its innovative cell therapy and drug development for solid tumors [1] Company Overview - Junshi Biosciences is a biotechnology company focused on developing safer, more effective, accessible, and affordable immune cell therapies for solid tumors, without being restricted by fixed molecular targets [1] - The company’s core product, GC101, is the world's first tumor-infiltrating lymphocyte (TIL) therapy that does not require high-intensity lymphodepletion chemotherapy or IL-2 administration, positioning it to potentially be the first TIL therapy approved for market in China [1] Market Position - The application for listing is supported by CICC as the exclusive sponsor, indicating a strategic move to enhance its market presence and funding capabilities [1] - According to Frost & Sullivan, the innovative approach of Junshi Biosciences could address some of the most common and difficult-to-treat solid tumors, highlighting its potential impact in the oncology market [1]